LEE'S PHARM.
李氏大藥廠

Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號:950)

李我同心 再次騰飛
A TRANSCENDING LEAP

First Quarterly Report 2021
第一季度業績報告

* For identification purpose only
僅供識別

QUARTERLY FINANCIAL STATEMENTS

The directors (the "**Directors**") of Lee's Pharmaceutical Holdings Limited (the "**Company**") present herewith the unaudited consolidated quarterly financial results (the "**Quarterly Results**") of the Company and its subsidiaries (collectively, the "**Group**") for the three months ended 31 March 2021, together with the comparative figures for the corresponding period in 2020. The Quarterly Results are unaudited, but have been reviewed by the Company's auditor, HLM CPA Limited (the "**Auditor**") in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants. The audit committee of the Company has also reviewed with the management and the Auditor this unaudited report for the three months ended 31 March 2021 before recommending it to the board of Directors for approval.

季度財務報表

李氏大藥廠控股有限公司(「**本公司**」)董事(「**董事**」)謹此呈列本公司及其附屬公司(統稱「**本集團**」)截至二零二一年三月三十一日止三個月之未經審核綜合季度財務業績(「**季度業績**」),連同二零二零年同期之比較數字。季度業績為未經審核,惟已由本公司核數師恒健會計師行有限公司(「**核數師**」)按照香港會計師公會頒佈之《香港審閱工作準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。在推薦予董事會批准之前,本公司審核委員會亦已與管理層及核數師一同審閱截至二零二一年三月三十一日止三個月之本未經審核報告。

BUSINESS REVIEW

First-quarter 2021 revenue of the Group totalled HK$283,142,000 (First-quarter 2020: HK$272,984,000), an increase of 3.7% compared to the prior-year quarter. First-quarter 2021 growths was primarily driven by the sales of Yallaferon®, Ferplex®, Slounase® and Treprostinil Injection which strongly grew by 96.6%, 41.1%, 40.8% and 160.2%, respectively, compensated the sales decline caused by the negative impacts such as the termination of the distribution of Zanidip® and the hospital re-listing of Livaracine® after the obtaining of drug registration approval as Nadroparin Calcium for Injection.

業務回顧

於二零二一年第一季度,本集團錄得總收益283,142,000港元(二零二零年第一季度:272,984,000港元),較去年同一季度增長3.7%。二零二一年第一季度的增長主要受《尤靖安》®、《菲普利》®、《速樂涓》®及曲前列尼爾注射液的銷售額分別強勁增長96.6%、41.1%、40.8%及160.2%帶動,抵銷了《再寧平》®特許授權終止及《立邁青》®於取得作為那屈肝素鈣注射液的藥品批准文號後需重新安排在醫院上市等負面影響所產生的銷售額跌幅。

Sales of licensed-in products in the first-quarter 2021 accounted for 55.6% (First-quarter 2020: 64.6%) of the Group's revenue while sales of proprietary and generic products in the first-quarter 2021 contributed 44.4% (First-quarter 2020: 35.4%) of the Group's revenue.

二零二一年第一季度引進產品的銷售額佔本集團收益的55.6%(二零二零年第一季度:64.6%),而二零二一年第一季度專利及仿製產品的銷售額則佔本集團收益的44.4%(二零二零年第一季度:35.4%)。

First-quarter 2021 gross profit of the Group was HK$192,411,000 (First-quarter 2020: HK$180,518,000). The Group's overall gross profit margin was 68.0%, improved by 1.9 percentage points as to 66.1% achieved in the first-quarter 2020 due to increase in proportion of revenue generated from the sales of proprietary and generic products.

於二零二一年第一季度,本集團錄得毛利192,411,000港元(二零二零年第一季度:180,518,000港元)。本集團整體的毛利率為68.0%,較二零二零年第一季度的66.1%上升1.9個百分點,源於專利及仿製產品銷售收益的佔比上升。

With the spin-off of ophthalmology unit taking place during the first-quarter 2021, research and development ("**R&D**") expenses recorded in the book represented new drugs development in major therapeutic areas such as cardiovascular, woman health, paediatrics, rare diseases, dermatology, obstetrics and urology, as well as in the area of oncology under a separate R&D arm within the Group. An aggregate of HK$76,530,000 (First-quarter 2020: HK$49,118,000) has been spent in the first-quarter 2021, represented 27.0% (First-quarter 2020: 18.0%) to the corresponding quarterly revenue. Among which HK$47,865,000 (First-quarter 2020: HK$25,368,000) has been recognised as expenses and HK$28,665,000 (First-quarter 2020: HK$23,750,000) has been capitalised as intangible assets. The Group's R&D activities resumed normal level in the first-quarter 2021, whereas that of in the first-quarter 2020 were significantly lower due to the COVID-19 pandemic.

隨着眼科項目於二零二一年第一季度進行分拆上市,賬目中錄得的研究及開發(「**研發**」)費用指心血管、女性健康、兒科、罕見病、皮膚科、產科及泌尿科等各種主要治療領域的新藥開發,以及獨立的腫瘤科研發分支。二零二一年第一季度總開支為76,530,000港元(二零二零年第一季度:49,118,000港元),佔相應季度收益的27.0%(二零二零年第一季度:18.0%),當中47,865,000港元(二零二零年第一季度:25,368,000港元)已確認為費用,而28,665,000港元(二零二零年第一季度:23,750,000港元)已資本化作為無形資產。本集團的研發活動於二零二一年第一季度回復正常水平,而二零二零年第一季度則因COVID-19大流行而顯著萎縮。

Following the establishment of Group Commercial Operations Centre ("**GCOC**"), special focus has been placed on strengthening existing and exploring new distribution channels as well as on the preparation for the roll-out of new and upcoming products and adequate resources has been deployed thereto. Overall, the selling expenses to revenue ratio during the first-quarter 2021 increased to 25.6%, compared to 24.2% same quarter last year.

繼集團營銷中心成立後，重點特別集中於強化現有分銷渠道，同時探索新分銷渠道，以及為新產品及即將面世的產品上市作準備，並投放足夠資源。整體而言，與去年同一季度的24.2%比較，二零二一年第一季度銷售費用對收益的比率上升至25.6%。

Net profit attributable to the owners of the Company in the first-quarter 2021 was HK$41,048,000, increased by 2.9% over the same quarter in 2020.

二零二一年第一季度的本公司擁有人應佔純利為41,048,000港元，較二零二零年同一季度增長2.9%。

During the quarter under review, the Group achieved good progress in production capacity expansions and manufacturing facility upgrades of Yallaferon® and Livaracine® in Hefei site. In Nansha site, the manufacturing of Tecarfarin tablet and Nokxaban tablet for GMP applications and clinical trials are actively moving forward in good progress. The equipment installation and commission for the manufacturing of inhaled pharmaceutical aerosols is also in progress. The equipment installation and commission for the productions of oral cytotoxic drugs and continuous glucose monitor were completed, and both facilities are ready for making clinical samples and/or registration batch.

於回顧季度，本集團合肥基地的《尤靖安》®及《立邁青》®產能提升及生產設施升級進度良好。南沙基地生產特卡法林藥片及諾克沙班藥片作GMP申請及臨床試驗的工作亦取得積極進展。製造吸入式霧化製劑的設備亦正在安裝及調試。生產口服細胞毒性藥物及進行連續血糖監測的設備則已完成安裝及調試，兩者均已為生產臨床樣品及／或註冊批次作好準備。

To date, the Group has over 40 projects from early- to late-stage development and measurable progress has been made during the quarter under review and up to date.

截至目前為止，本集團有超過40個處於發展初期至後期階段的項目，且於回顧季度及迄今的進度良好。

Major Therapeutic Areas

Cetraxal® Plus

On 4 January 2021, the Group recruited its first patient dosed with Cetraxal® Plus an ear drops product licensed from Laboratorios Salvat S.A. targeting acute otitis externa (AOE), and acute otitis media with tympanostomy tubes (AOMT) in a Phase III clinical trial in China.

Intrarosa®

On 5 January 2021, the Group has been granted the clinical trial approval from the China's National Medical Products Administration ("**NMPA**") to initiate a Phase III, multicentre, randomised, double blinded, parallel group clinical trial of Intrarosa®, a product licensed from Endoceutics, Inc., in the treatment of vulvovaginal atrophy ("**VVA**"). The preparation work for this pivotal Phase III study is in progress and is expected to initiate patient recruitment in July 2021. Intrarosa® is the only U.S. Food and Drug Administration ("**FDA**") approved, locally administered, daily non-estrogen steroid for the treatment of moderate to severe dyspareunia (pain during intercourse), a symptom of VVA, due to menopause. Intrarosa®'s product information does not have any boxed (safety) warnings, contrary to all other FDA approved drugs for the treatment of VVA, which have boxed warnings. Intrarosa® contains prasterone, also known as dehydroepiandrosterone (DHEA). Prasterone is an inactive endogenous steroid, which is converted locally into androgens and estrogens to help restore the vaginal tissue as indicated by improvements in the percentage of superficial and parabasal cells, and pH.

主要治療領域

Cetraxal®Plus

於二零二一年一月四日，本集團於中國招募首名病人在三期臨床試驗中使用 Cetraxal®Plus 。Cetraxal®Plus 為 Laboratorios Salvat S.A.特許授權的滴耳液產品，治療急性外耳道炎及伴有鼓膜置管的急性中耳炎。

Intrarosa®

於二零二一年一月五日，本集團已獲中國國家藥品監督管理局(「**國家藥監局**」)批授開展Intrarosa®的多中心、隨機、雙盲、並行組別的三期臨床試驗的臨床試驗批准。Intrarosa®為Endoceutics, Inc.特許授權的產品，用於治療外陰陰道萎縮(「**VVA**」)。此關鍵的第三期研究正在籌備當中，預期於二零二一年七月開始招募患者。Intrarosa®是唯一一種獲美國食物及藥物管理局(「**FDA**」)認證供日常局部使用的不含雌激素類固醇，用於治療因更年期而出現的中等至嚴重程度的性交疼痛(性交時產生的疼痛，為一種VVA徵狀)。Intrarosa®的產品資料並無任何包裝(安全)警告，有別於其他獲FDA認證用於治療VVA的藥物，全部均印有包裝警告。Intrarosa®含有普拉雄酮(又名脫氫表雄酮(DHEA))。普拉雄酮為一種非活性內源性類固醇，會內部轉化為雄激素及雌激素，幫助修復陰道纖維組織，從表層和副基底細胞的百分比以及酸鹼值改善可見一斑。

Lutrate®

On 27 January 2021, the New Drug Application ("**NDA**") of Lutrate® Depot (leuprolide acetate for depot suspension) 3.75 mg 1-month administration ("**Lutrate®**") for the palliative treatment of advanced prostate cancer has been accepted for review by NMPA. Lutrate® contains the active ingredient leuprolide acetate which belongs to a group of drugs called luteinising hormone-releasing hormone ("**LHRH**") agonists that reduce testosterone – the major androgen. Treatment with LHRH agonists is the predominant form of androgen deprivation therapy and has become the standard of care for metastatic prostatic cancer.

Staccato® fentanyl

Staccato® fentanyl for inhalation system is a combination drug-device delivery product designed for rapid, systemic delivery of aerosolised fentanyl via the lung. The product integrates the latest technology with a unique drug delivery technology, ensuring efficacy while deterring abuse and preventing overdose. The coming Phase I/IIa multicentre study in China is designed to evaluate the efficacy and safety of Staccato® fentanyl in treating breakthrough pain in patients with cancer. The study will be comprised of two stages: stage one study is designed to determine the recommended dosage; and stage two study will be a pharmacokinetic (PK) study based on the recommended dosage which can get the patients relieved from the pain in stage one. The preparation work for this Phase I/IIa clinical trial of Staccato® fentanyl is in progress and is expected to initiate patient recruitment in July 2021.

Lutrate®

於二零二一年一月二十七日，Lutrate® Depot(醋酸亮丙瑞林長效懸浮液)3.75毫克1個月輸注(「**Lutrate®**」)的新藥申請已獲國家藥監局受理，該藥物乃用於晚期前列腺癌的紓緩治療。Lutrate®含有活性成份醋酸亮丙瑞林，屬於一組名為促黃體激素釋放激素(「**LHRH**」)促進劑的藥物，可減少主要雄激素睪酮。以LHRH促進劑進行治療為雄激素去除療法的主要方式，現已成為轉移性前列腺癌的護理標準。

Staccato®芬太尼

Staccato®芬太尼吸入製劑是一種複合型吸入式給藥裝置，其設計是透過肺部迅速及規律地吸入霧化芬太尼。此項產品結合具有獨特給藥技術的最新科技，於確保藥效的同時防止濫用及過量用藥。即將於中國進行的一／二a期多中心研究專門評估Staccato®芬太尼在治療癌症病患的爆發性癌痛的藥效及安全程度。研究將分為兩個階段：第一階段研究專責釐定建議劑量；而第二階段研究將基於第一階段能夠紓緩病患痛楚的建議劑量，進行藥物代謝動力學研究。此項Staccato®芬太尼的第一／二a期臨床試驗正在籌備當中，預期於二零二一年七月開始招募病人。

GCC-4401C

On 1 March 2021, the Group has been granted the approval of the Investigational New Drug ("**IND**") application of GCC-4401C from the NMPA to conduct clinical trials investigating GCC-4401C as a potential treatment for cirrhotic patients with non-tumoral portal vein thrombosis (PVT). GCC-4401C is a novel direct oral anticoagulant with structural similarity to rivaroxaban. It directly inhibits the activity of factor Xa, an important validated target in the blood coagulation pathway, to prevent thrombosis.

During the quarter under review and up to date, the Group obtained 2 NDA and Abbreviated New Drug Application ("**ANDA**") approvals from NMPA.

Fondaparinux Sodium Injection

On 2 February 2021, Fondaparinux Sodium Injection (0.5 ml: 2.5 mg), a drug indicated to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg), which can lead to pulmonary embolism (PE; a blood clot in the lung), in people who are having hip surgery, hip or knee replacement, or abdominal surgery, obtained approval for manufacturing and marketing from the NMPA. Fondaparinux sodium is a synthetic and specific inhibitor of coagulation activated factor X (factor Xa) with high bioavailability, fast acting and longer half-life. It has no effect on factor IIa, and has low bleeding adverse event. It inhibits only free factor Xa but not factor Xa bound to the prothrombinase. Use of fondaparinux does not require monitoring of PT (prothrombin time) and aPTT (activated partial thromboplastin time). The short chain length of fondaparinux sodium results in devoid of immunogenicity. It does not interact with platelet and does not induce thrombocytopenia. It has no hepatotoxicity and has less allergic reactions.

GCC-4401C

於二零二一年三月一日，本集團獲國家藥監局批准GCC-4401C的新藥臨床試驗申請，以對GCC-4401C作為可能治療非腫瘤性門靜脈血栓(PVT)的肝硬化患者進行臨床試驗。GCC-4401C為一種與rivaroxaban結構類似的新型直接口服抗凝血劑。凝血因子Xa為血液凝固路徑中的重要靶點，GCC-4401C直接抑制凝血因子Xa的活動，以防止血栓形成。

於回顧季度及截至目前為止，本集團已取得國家藥監局發出2項新藥申請及簡化新藥申請批准。

磺達肝癸鈉注射液

於二零二一年二月二日，磺達肝癸鈉注射液(0.5毫升：2.5毫克)已獲國家藥監局的生產及上市批文。該藥物適用於預防正進行髖關節手術、髖關節或膝關節置換或下腹手術的人士出現可導致肺栓塞(PE；肺部血凝塊)的深靜脈血栓(DVT；一般見於腿部的血凝塊)。磺達肝癸鈉乃人工合成的活化凝血X因子(Xa因子)選擇性抑制劑，具有生物利用度高、起效快、半衰期長等優點。磺達肝癸鈉對IIa因子無作用，出血的不良反應少，僅抑制游離的Xa因子而不抑制與凝血酶原酶結合的Xa因子，不需監測PT(凝血酶原時間)及aPTT(活化部分凝血酶時間)。磺達肝癸鈉分子鏈短，不能誘導抗體反應，與血小板並無相互作用，不會引起血小板減少症，且對肝臟無毒害作用，過敏反應發生少。

Sodium Phenylbutyrate Granules

On 13 May 2021, the Drug Registration Certificate for Sodium Phenylbutyrate Granules (specification: 150g/bottle, containing 0.94g Sodium Phenylbutyrate for every 1g) developed and manufactured by Zhaoke Pharmaceutical (Guangzhou) Company Limited ("**Zhaoke Guangzhou**"), a wholly-owned subsidiary of the Company, has been obtained from the NMPA. Sodium Phenylbutyrate is used as an adjuvant treatment for long-term treatment on urea cycle disorders patients resulting from carbamoyl phosphate synthetase deficiency, ornithine transcarbamylase deficiency or argininosuccinate synthetase deficiency. It is applicable to new-born babies (born less than 28 days) with profound biotinidase deficiency and to patients with a history of late-onset hyperammonemia brain dysfunction (partial biotinidase deficiency, born for more than one month). The Sodium Phenylbutyrate Granules developed and manufactured by Zhaoke Guangzhou is the first generic version in China. As there is no original Sodium Phenylbutyrate available for sale in China, the Group's Sodium Phenylbutyrate Granules would address the unmet medical needs in China.

苯丁酸鈉顆粒

於二零二一年五月十三日，由本公司全資附屬公司兆科藥業(廣州)有限公司(「**兆科廣州**」)開發並生產的苯丁酸鈉顆粒(規格：150克／瓶，每1克含苯丁酸鈉0.94克)獲國家藥監局的藥品註冊證書。苯丁酸鈉作為輔助治療藥物，用於氨基甲醯磷酸合成酶缺乏症、鳥氨酸氨甲醯基轉移酶缺乏症或精氨基琥珀酸合成酶缺乏症引起的尿素循環異常患者的長期治療，適用於新生兒期(出生28天內)出現完全酶缺乏症的患者，亦適用於有高血氨性腦病病史的遲發型(部分酶缺乏症，發生於出生1個月後)患者。兆科廣州開發並生產的苯丁酸鈉顆粒為國內首仿藥物。目前中國沒有原研苯丁酸鈉銷售，本集團的苯丁酸鈉顆粒正好填補國內的空白。

Oncology Pipeline Highlights

China Oncology Focus Limited ("**COF**"), a 65% owned subsidiary of the Group, is the Group's R&D arm in the area of oncology. To date, there are 10 oncology assets, including 5 innovative and 5 generic, in development for the treatment of a range of cancers.

Socazolimab in recurrent and metastatic cervical cancer

On 5 February 2021, the breakthrough therapy designation ("**BTD**") has been granted by the NMPA to COF for its Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as ZKAB001) to treat recurrent and metastatic cervical cancer. Socazolimab is a fully human anti PD-L1 monoclonal antibody targeting tumor PD-L1 protein. It can release the "brake" causing by the tumor cell to the immune system. To date, Centre for Drug Evaluation has provided feedbacks in respect of the pre-NDA meetings and NDA submission is expected by end of June 2021.

Socazolimab in osteosarcoma

During the quarter under review and up to date, the registration enabling Phase III clinical trial using Socazolimab in osteosarcoma is in good progress. To date, 83 patients have been enrolled.

腫瘤管道重點

本集團擁有65%權益的附屬公司中國腫瘤醫療有限公司(「**COF**」)為本集團在腫瘤科方面的研發分支。截至目前為止，10項腫瘤產品正在開發，包括5項創新及5項仿製藥，用於治療多種癌症。

使用Socazolimab的復發或轉移性宮頸癌治療

於二零二一年二月五日，COF用於治療復發性或轉移性宮頸癌的抗PD-L1單克隆抗體Socazolimab(前稱ZKAB001)獲得國家藥監局突破性療法認定。Socazolimab為針對腫瘤PD-L1蛋白的完全人類抗PD-L1單克隆抗體，可以釋放由腫瘤細胞引起的免疫系統「剎車」。截至目前為止，藥品審評中心已就新藥申請前會議提供回饋，新藥申請預計將於二零二一年六月底或之前提交。

使用Socazolimab的骨肉瘤治療

於回顧季度及截至目前為止，使用Socazolimab的骨肉瘤維持治療可望達成註冊的三期臨床試驗進度良好。迄今已招募83名患者。

Socazolimab combined with chemotherapy in small-cell lung cancer

On 1 March 2021, COF has been granted the clinical trial application approval from the NMPA to conduct a Phase III, multicentre, randomised, double blinded, parallel-group clinical trial of Socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. The approval is based on the results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed promising efficacy and safety profile in patients with extensive-stage small-cell lung cancer. This clinical trial will be led by Prof. Shun Lu (陸舜) from Shanghai Chest Hospital (上海市胸科醫院) and is expected to initiate patient recruitment in July 2021.

使用Socazolimab結合化療治療小細胞肺癌

於二零二一年三月一日，COF獲國家藥監局批准臨床試驗申請，以對結合化療一線治療擴散期小細胞肺癌的Socazolimab進行多中心、隨機、雙盲、並行組別的第三期臨床試驗。該批准的依據為先前第一b期試驗的結果，當中結合卡鉑和依託泊苷的Socazolimab在擴散期小細胞肺癌患者中表現出良好的療效及安全性。此臨床試驗將由上海市胸科醫院陸舜教授牽頭，預期將於二零二一年七月開展患者招募。

Business Partnership

The in-licensing approach is the Group's preferred mode of business development strategy. Nevertheless, the Group has remained selective in entering new in-licensing deals. In addition, the Group has achieved a new breakthrough of business during the quarter under review. On 2 March 2021, a distribution agreement with Kunming Baker Norton Pharmaceutical Sales Co., Ltd. ("**KBNS**"), a wholly-owned subsidiary of KPC Pharmaceuticals, Inc. ("**KPC**", stock code: 600422.SH), had become effective and pursuant to which exclusive promotion right of Fondaparinux Sodium Injection (磺達肝癸鈉注射液) (0.5 ml: 2.5 mg) in 18 provinces in China including Jiangsu, Zhejiang, Henan and Shandong, etc, has been granted to KBNS. The Group believed that the collaboration with KPC shall enable the Group to leverage on KPC's proven sales force on new products promotion.

業務夥伴

特許經營策略為本集團業務發展策略的首選模式。然而，本集團在訂立新的特許經營交易時，仍然堅持精挑細選。此外，本集團更於回顧季度取得新的業務突破。於二零二一年三月二日，與昆藥集團股份有限公司(「**KPC**」，股份代號：600422.SH)的全資附屬公司昆明貝克諾頓藥品銷售有限公司(「**KBNS**」)簽訂的產品銷售服務協議生效，據此，KBNS獲授磺達肝癸鈉注射液(0.5毫升：2.5毫克)於中國18個省份(包括江蘇、浙江、河南及山東等)的獨家推廣權。本集團相信，與KPC合作可讓本集團借助KPC往績良好的銷售能力推廣新產品。

Corporate Development

The Group believes that the spin-off of certain R&D arms, such as ophthalmology and oncology projects, into standalone companies will in turn drive the market to recognise the value of its robust pipelines. A major milestone has been achieved by one of those arms on 29 April 2021 when its investment in Zhaoke Ophthalmology Limited ("**ZKO**", stock code: 6622.HK) has been successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited and the final offer price was HK$16.80 per ZKO share. Following completion of the listing thereof, ZKO ceased to be an associate of the Company since the Group will not exercise significant influence over the operation of ZKO. The Group's investment in ZKO is hence accounted for as financial assets at fair value through other comprehensive income for financial reporting purposes. The Group will record a gain of approximately HK$2.32 billion in the Company's consolidated statement of profit or loss on this derecognition of investment in ZKO as an associate of the Company in the second quarter of 2021.

企業發展

本集團相信，將眼科及腫瘤科項目等若干研發部門分拆為獨立公司將推動市場認識本集團各管道的價值。於二零二一年四月二十九日，於其中一個研發部門的投資樹立重大里程碑，即兆科眼科有限公司(「**兆科眼科**」，股份代號：6622.HK)成功於香港聯合交易所有限公司主板上市，最終發售價為每股兆科眼科股份16.80港元。於兆科眼科完成上市後，由於本集團不能再對兆科眼科的運作行使重大影響力，故兆科眼科不再為本公司的聯營公司。因此，本集團於兆科眼科的投資就財務報告而言入賬列作按公平值透過其他全面收益列賬的財務資產。於二零二一年第二季終止將本公司於兆科眼科的投資確認為聯營公司時，本集團將於本公司的綜合損益表內錄得收益約2,320,000,000港元。

PROSPECTS

The Group remains of the view that the tough environment will be persisted in 2021 and foresees that pressure on drug prices will be one of the key challenges to industry players as China adopts a progressively more dynamic approach to National Reimbursement Drug List updates. The central government has completed the fourth round of national volume-based procurement ("**VBP**") in February 2021, followed by a notice released by Joint Procurement Office in early May 2021 mentioned the collection of relevant drug information for the China's fifth round of VBP. Nevertheless, positive catalysts such as the containment of COVID-19 pandemic in China and the re-opening of economy within the region, the newly approved products to be launched, and the transformed sales force led by the GCOC, may drive the Group to overcome the challenges. In addition, it is believed that the Group would be eventually benefited from the new laws and regulations for the pharmaceutical industry in the long run, and the Group will continue to stay focus on its new drug development and cost containment in order to differentiate itself from other pharmaceutical companies.

Following the completion of the spin-off of ZKO in April 2021, the Group can now spare more resources to develop its business in major therapeutic areas. Besides, the Group will endeavour to continue its efforts to seek opportunities on the fundraising and possible spin-off of its oncology R&D arm in the near future.

The Group firmly believes that all these works to be done will eventually drive growth therefor and will eventually create more value for the shareholders.

展望

本集團依然相信，二零二一年的環境仍將荊棘滿途，預料隨着中國逐步採納更靈活的國家醫保藥品目錄更新政策，藥物價格壓力將繼續為業界帶來挑戰。中央政府於二零二一年二月完成第四批國家組織藥品集中採購(「**藥品集採**」)，聯合採購辦公室隨後於二零二一年五月初發出通知，表示就中國第五批藥品集採收集相關藥品信息。然而，在中國遏止COVID-19疫情、區內經濟重啟、新批產品即將面市及集團營銷中心帶領銷售團隊轉型等有利因素推動下，預期本集團將能克服各種挑戰。此外，本集團相信長遠終將受惠於醫藥行業的新法律及法規，故本集團將繼續專注開發新藥及控制成本，以期從眾多藥業公司中脫穎而出。

隨着兆科眼科於二零二一年四月完成分拆上市，本集團目前可投放更多資源開拓其主要治療領域的業務。此外，本集團亦將繼續努力探索集資機會以及於短期內將腫瘤科研發部門分拆的可能性。

本集團深信，上述各項任務將可成就增長，最終為股東創造更高價值。

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

簡明綜合損益表

For the three months ended 31 March 2021

截至二零二一年三月三十一日止三個月

		Notes 附註	For the three months ended 31 March 截至三月三十一日止三個月 2021 二零二一年 HK$'000 千港元 (unaudited) (未經審核)	2020 二零二零年 HK$'000 千港元 (unaudited) (未經審核)
Revenue	收益	3	**283,142**	272,984
Cost of sales	銷售成本		**(90,731)**	(92,466)
Gross profit	毛利		**192,411**	180,518
Other income	其他收益	4	**31,581**	12,310
Other gains and losses, net	其他收益及虧損淨額		**2,349**	(1,489)
Selling and distribution expenses	銷售及分銷費用		**(72,569)**	(65,929)
Administrative expenses	行政費用		**(58,871)**	(49,795)
Reversal of (provision for) expected credit losses on financial assets	財務資產預期信貸虧損撥回(撥備)		**330**	(211)
Research and development expenses	研究及開發費用		**(47,865)**	(25,368)
Profit from operations	經營溢利		**47,366**	50,036
Finance costs	財務成本		**(1,271)**	(1,582)
Share of results of associates	分佔聯營公司業績		**(2,264)**	(3,062)
Profit before taxation	除税前溢利		**43,831**	45,392
Taxation	税項	5	**(7,475)**	(11,394)
Profit for the period	本期間溢利		**36,356**	33,998
Attributable to:	下列人士應佔：			
Owners of the Company	本公司擁有人		**41,048**	39,896
Non-controlling interests	非控股權益		**(4,692)**	(5,898)
			36,356	33,998
			HK cents 港仙	HK cents 港仙
Earnings per share:	每股盈利：	6		
Basic	基本		**6.98**	6.78
Diluted	攤薄		**6.97**	6.78

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the three months ended 31 March 2021

簡明綜合損益及其他全面收益表

截至二零二一年三月三十一日止三個月

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 二零二一年	2020 二零二零年
		HK$'000 千港元	HK$'000 千港元
		(unaudited) (未經審核)	(unaudited) (未經審核)
Profit for the period	本期間溢利	**36,356**	33,998
Other comprehensive expense:	其他全面開支：		
Items that may be reclassified subsequently to profit or loss:	其後可能重新分類至損益之項目：		
– Exchange differences on translation of financial statements of overseas subsidiaries	－海外附屬公司財務報表換算之匯兑差額	**(7,062)**	(24,150)
– Share of other comprehensive expense of associates	－分佔聯營公司之其他全面開支	**(54)**	(99)
Item that will not be reclassified subsequently to profit or loss:	其後不會重新分類至損益之項目：		
– Fair value changes of financial assets at fair value through other comprehensive income	－按公平值透過其他全面收益列賬之財務資產之公平值變動	**(91,196)**	(126,616)
Other comprehensive expense for the period, net of tax	本期間其他全面開支，扣除税項	**(98,312)**	(150,865)
Total comprehensive expense for the period	本期間全面開支總額	**(61,956)**	(116,867)
Total comprehensive expense for the period attributable to:	下列人士應佔本期間全面開支總額：		
Owners of the Company	本公司擁有人	**(53,047)**	(102,996)
Non-controlling interests	非控股權益	**(8,909)**	(13,871)
		(61,956)	(116,867)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

簡明綜合權益變動表

For the three months ended 31 March 2021

截至二零二一年三月三十一日止三個月

		Attributable to the owners of the Company 本公司擁有人應佔										
		Share capital 股本 HK$'000 千港元	Share premium 股份溢價 HK$'000 千港元	Merger difference 合併差額 HK$'000 千港元	Share-based compensation reserve 以股份支付之酬金儲備 HK$'000 千港元	Other reserves 其他儲備 HK$'000 千港元	Investments revaluation reserve 投資重估儲備 HK$'000 千港元	Exchange reserve 匯兌儲備 HK$'000 千港元	Retained profits 保留溢利 HK$'000 千港元	Sub-total 小計 HK$'000 千港元	Attributable to non-controlling interests 非控股權益應佔 HK$'000 千港元	Total 總計 HK$'000 千港元
At 1 January 2021 (audited)	於二零二一年一月一日(經審核)	29,406	714,813	9,200	40,847	65,228	(254,155)	(14,843)	1,559,299	2,149,795	(34,417)	2,115,378
Employee share option benefits	僱員購股權福利	-	-	-	3,533	-	-	-	-	3,533	-	3,533
Share of reserve of an associate	分佔一間聯營公司之儲備	-	-	-	-	14	-	-	-	14	-	14
Profit (loss) for the period	本期間溢利(虧損)	-	-	-	-	-	-	-	41,048	41,048	(4,692)	36,356
Other comprehensive expense for the period	本期間其他全面開支											
- Exchange differences on translation of financial statements of overseas subsidiaries	-海外附屬公司財務報表換算之匯兌差額	-	-	-	-	-	-	(7,006)	-	(7,006)	(56)	(7,062)
- Share of other comprehensive expense of associates	-分佔聯營公司之其他全面開支	-	-	-	-	(54)	-	-	-	(54)	-	(54)
- Fair value changes of financial assets at fair value through other comprehensive income	-按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	-	(87,035)	-	-	(87,035)	(4,161)	(91,196)
Total comprehensive (expense) income for the period	本期間全面(開支)收益總額	-	-	-	-	(54)	(87,035)	(7,006)	41,048	(53,047)	(8,909)	(61,956)
At 31 March 2021 (unaudited)	於二零二一年三月三十一日(未經審核)	29,406	714,813	9,200	44,380	65,188	(341,190)	(21,849)	1,600,347	2,100,295	(43,326)	2,056,969

		Attributable to the owners of the Company 本公司擁有人應佔										
		Share capital 股本 HK$'000 千港元	Share premium 股份溢價 HK$'000 千港元	Merger difference 合併差額 HK$'000 千港元	Share-based compensation reserve 以股份支付之酬金儲備 HK$'000 千港元	Other reserves 其他儲備 HK$'000 千港元	Investments revaluation reserve 投資重估儲備 HK$'000 千港元	Exchange reserve 匯兌儲備 HK$'000 千港元	Retained profits 保留溢利 HK$'000 千港元	Sub-total 小計 HK$'000 千港元	Attributable to non-controlling interests 非控股權益應佔 HK$'000 千港元	Total 總計 HK$'000 千港元
At 1 January 2020 (audited)	於二零二零年一月一日（經審核）	29,396	714,146	9,200	23,675	157,404	(8,386)	(97,707)	1,468,172	2,295,900	181,538	2,477,438
Employee share option benefits	僱員購股權福利	-	-	-	1,386	-	-	-	-	1,386	-	1,386
Exercise of share options	行使購股權	10	667	-	(231)	-	-	-	-	446	-	446
Share options lapsed	已失效購股權	-	-	-	(39)	-	-	-	39	-	-	-
Share of reserve of an associate	分佔一間聯營公司之儲備	-	-	-	-	14	-	-	-	14	-	14
Capital injection by non-controlling interests	非控股權益出資	-	-	-	-	-	-	-	-	-	31,226	31,226
Profit (loss) for the period	本期間溢利(虧損)	-	-	-	-	-	-	-	39,896	39,896	(5,898)	33,998
Other comprehensive expense for the period	本期間其他全面開支											
- Exchange differences on translation of financial statements of overseas subsidiaries	-海外附屬公司財務報表換算之匯兌差額	-	-	-	-	-	-	(21,334)	-	(21,334)	(2,816)	(24,150)
- Share of other comprehensive expense of associates	-分佔聯營公司之其他全面開支	-	-	-	-	(99)	-	-	-	(99)	-	(99)
- Fair value changes of financial assets at fair value through other comprehensive income	-按公平值透過其他全面收益列賬之財務資產之公平值變動	-	-	-	-	-	(121,459)	-	-	(121,459)	(5,157)	(126,616)
Total comprehensive (expense) income for the period	本期間全面(開支)收益總額	-	-	-	-	(99)	(121,459)	(21,334)	39,896	(102,996)	(13,871)	(116,867)
At 31 March 2020 (unaudited)	於二零二零年三月三十一日（未經審核）	29,406	714,813	9,200	24,791	157,319	(129,845)	(119,041)	1,508,107	2,194,750	198,893	2,393,643

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three months ended 31 March 2021

未經審核簡明綜合財務報表附註

截至二零二一年三月三十一日止三個月

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standards ("**HKASs**") issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**") as well as with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

1. 編製基準

未經審核簡明綜合財務報表乃按照香港會計師公會頒佈之香港會計準則以及香港聯合交易所有限公司證券上市規則附錄十六之適用披露規定編製。

2. PRINCIPAL ACCOUNTING POLICIES

The unaudited condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values as appropriate.

The unaudited condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2020.

The accounting policies and methods of computation used in preparing the unaudited condensed consolidated financial statements for the three months ended 31 March 2021 are consistent with those used in the Group's annual financial statements for the year ended 31 December 2020 except as described below.

2. 主要會計政策

未經審核簡明綜合財務報表乃按歷史成本基準編製，惟若干財務工具按公平值計量(視適用情況而定)除外。

未經審核簡明綜合財務報表不包括須於全年財務報表提供之所有資料及披露事項，並應與本集團截至二零二零年十二月三十一日止年度之全年財務報表一併閱讀。

編製截至二零二一年三月三十一日止三個月之未經審核簡明綜合財務報表所用之會計政策及計算方法與本集團截至二零二零年十二月三十一日止年度之全年財務報表所用者一致，惟下述者除外。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

In the current reporting period, the Group has applied, for the first time, the following amendments to HKASs and Hong Kong Financial Reporting Standards ("**HKFRSs**") issued by the HKICPA that are relevant for the preparation of the Group's unaudited condensed consolidated financial statements:

Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16	Interest Rate Benchmark Reform – Phase 2
Amendments to HKFRS 16	COVID-19-Related Rent Concessions

The application of these amendments to HKASs and HKFRSs has had no material effect on the amounts reported in these unaudited condensed consolidated financial statements and/or disclosures set out in these unaudited condensed consolidated financial statements.

2. 主要會計政策(續)

於本報告期間內，本集團首次應用香港會計師公會所頒佈就編製本集團未經審核簡明綜合財務報表而言相關之下列香港會計準則及香港財務報告準則之修訂：

香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號之修訂	利率基準改革－第2階段
香港財務報告準則第16號之修訂	COVID-19相關租金優惠

應用該等香港會計準則及香港財務報告準則之修訂對本未經審核簡明綜合財務報表所呈報之金額及／或本未經審核簡明綜合財務報表所載之披露事項並無重大影響。

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

The Group has not early applied the following new and amendments to HKASs and HKFRSs that have been issued but are not yet effective:

Accounting Guideline 5 (Revised)	Merger Accounting for Common Control Combination[1]
HKFRS 17	Insurance Contracts and the related Amendments[2]
Amendments to HKAS 1	Classification of Liabilities as Current and Non-current or related amendments to Hong Kong Interpretation 5 (2020)[2]
Amendments to HKAS 1	Disclosure of Accounting Policies[2]
Amendments to HKAS 8	Definition of Accounting Estimates[2]
Amendments to HKAS 16	Property, Plant and Equipment – Proceeds before Intended Use[1]
Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract[1]
Amendments to HKFRS 3	Reference to the Conceptual Framework[1]
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[3]
Amendments to HKFRSs	Annual Improvements to HKFRSs 2018–2020[1]

1 Effective for annual periods beginning on or after 1 January 2022, earlier application is permitted

2 Effective for annual periods beginning on or after 1 January 2023, earlier application is permitted

3 Effective date to be determined

2. 主要會計政策(續)

本集團並無提早採用下列已頒佈但尚未生效之新增香港會計準則及香港財務報告準則以及香港會計準則及香港財務報告準則之修訂：

會計指引第5號（修訂）	共同控制下業務合併之合併會計處理[1]
香港財務報告準則第17號	保險合約及相關修訂[2]
香港會計準則第1號之修訂	流動及非流動負債之分類或香港詮釋第5號（二零二零年）之相關修訂[2]
香港會計準則第1號之修訂	會計政策披露[2]
香港會計準則第8號之修訂	會計估計定義[2]
香港會計準則第16號之修訂	物業、廠房及設備－作擬定用途前之所得款項[1]
香港會計準則第37號之修訂	虧損合約－履行合約之成本[1]
香港財務報告準則第3號之修訂	提述概念框架[1]
香港財務報告準則第10號及香港會計準則第28號之修訂	投資者與其聯營公司或合營企業之間之資產出售或注資[3]
香港財務報告準則之修訂	香港財務報告準則二零一八年至二零二零年之年度改進[1]

1 於二零二二年一月一日或之後開始之年度期間生效，可提早應用

2 於二零二三年一月一日或之後開始之年度期間生效，可提早應用

3 生效日期待定

2. PRINCIPAL ACCOUNTING POLICIES (CONTINUED)

The Group has already commenced an assessment of the impact of these new and amendments to HKASs and HKFRSs but is not yet in a position to state whether these new and amendments to HKASs and HKFRSs would have a material impact on its results of operations and financial positions.

2. 主要會計政策(續)

本集團已開始評估該等新增香港會計準則及香港財務報告準則以及香港會計準則及香港財務報告準則之修訂之影響，但尚無法說明該等新增香港會計準則及香港財務報告準則以及香港會計準則及香港財務報告準則之修訂會否對本集團之經營業績及財務狀況造成重大影響。

3. REVENUE

The principal activities of the Group are the developing, manufacturing and sales and marketing of pharmaceutical products. During the period, revenue represents the net amount received and receivable for goods sold by the Group to outside customers and are recognised at point in time as follows:

3. 收益

本集團之主要業務為開發、製造、銷售及推廣藥品。於期內，收益乃指本集團向外部客戶出售貨品之已收及應收款項淨額，並按時間點確認如下：

Business segments

業務分部

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 二零二一年	2020 二零二零年
		HK$'000 千港元	HK$'000 千港元
		(unaudited) (未經審核)	(unaudited) (未經審核)
Proprietary and generic products	專利及仿製產品	**125,612**	96,629
Licensed-in products	引進產品	**157,530**	176,355
		283,142	272,984

3. REVENUE (CONTINUED)

Geographical segments

During the three months ended 31 March 2021 and 2020, more than 90% of the Group's revenue was derived from activities conducted in the People's Republic of China (the "**PRC**"), no geographical segmental information is presented.

3. 收益(續)

地區分部

於截至二零二一年及二零二零年三月三十一日止三個月，本集團逾90%之收益源自於中華人民共和國(「**中國**」)進行之業務，故此並無呈列地區分部資料。

4. OTHER INCOME

4. 其他收益

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 **二零二一年** **HK$'000** **千港元** **(unaudited)** **(未經審核)**	2020 二零二零年 HK$'000 千港元 (unaudited) (未經審核)
Interest income on:	下列各項之利息收入：		
Bank and pledged bank deposits	銀行及已抵押銀行存款	**837**	2,767
Advance to associates	墊付予聯營公司之款項	**751**	426
Total interest income	利息收入總額	**1,588**	3,193
Development and government grants	開發及政府補助	**4,781**	8,050
Rental and utilities income	租金及公共服務收入	**2,815**	300
Research and development service income	研究及開發服務收入	**21,671**	30
Sundry income	雜項收入	**726**	737
		31,581	12,310

The Group received the development grants from local government as recognition of the Group's performance and development of high-technology pharmaceutical products.

本集團收到地方政府認可本集團表現及開發高新科技藥品而授予之開發補助。

5. TAXATION

5. 稅項

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 二零二一年 HK$'000 千港元 (unaudited) (未經審核)	2020 二零二零年 HK$'000 千港元 (unaudited) (未經審核)
Current tax	現時稅項		
Hong Kong Profits Tax	香港利得稅	**7,360**	7,242
PRC Enterprise Income Tax	中國企業所得稅	**912**	–
		8,272	7,242
Deferred tax	遞延稅項		
Origination and reversal of temporary difference	產生及撥回暫時差額	**(797)**	4,152
		7,475	11,394

For a qualified entity, Hong Kong Profits Tax for the three months ended 31 March 2021 and 2020 is calculated at 8.25% on the first HK$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK$2 million according to the two-tiered profits tax rates regime. Hong Kong Profits Tax is calculated at 16.5% for the three months ended 31 March 2021 and 2020 for all other entities.

就合資格實體而言，按照利得稅兩級制，截至二零二一年及二零二零年三月三十一日止三個月之香港利得稅就首2百萬港元估計應課稅溢利按8.25%及就2百萬港元以上估計應課稅溢利按16.5%計算。就所有其他實體而言，截至二零二一年及二零二零年三月三十一日止三個月之香港利得稅均按16.5%計算。

Tax arising in the PRC is calculated at the tax rates prevailing in the PRC. Taxation arising in other jurisdictions is calculated at the tax rate prevailing in the relevant jurisdictions.

於中國產生之稅項按中國現行稅率計算。於其他司法權區產生之稅項按有關司法權區之現行稅率計算。

6. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

6. 每股盈利

本公司擁有人應佔每股基本及攤薄盈利乃基於下列數據計算：

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 **二零二一年** **HK$'000** **千港元** **(unaudited)** **（未經審核）**	2020 二零二零年 HK$'000 千港元 (unaudited) （未經審核）
Earnings:	盈利：		
Net profit attributable to the owners of the Company for the purpose of basic and diluted earnings per share	就計算每股基本及攤薄盈利而言之本公司擁有人應佔純利	**41,048**	39,896

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 **二零二一年** **Share(s) '000** **千股** **(unaudited)** **（未經審核）**	2020 二零二零年 Share(s) '000 千股 (unaudited) （未經審核）
Number of shares:	股份數目：		
Weighted average number of ordinary shares for the purpose of basic earnings per share	就計算每股基本盈利而言之普通股加權平均數	**588,125**	588,105
Effect of dilutive potential ordinary shares:	潛在攤薄普通股之影響：		
Options	購股權	**569**	12
Weighted average number of ordinary shares for the purpose of diluted earnings per share	就計算每股攤薄盈利而言之普通股加權平均數	**588,694**	588,117

7. RELATED PARTY TRANSACTIONS

During the reporting period, the Group entered into the following transactions with related parties. In the opinion of the directors of the Company, the following transactions arose in the ordinary course of the Group's business.

7. 關聯方交易

於報告期間內，本集團已與關聯方進行以下交易。本公司董事認為，下列交易乃於本集團日常業務過程中產生。

(a) Transaction with associates

(a) 與聯營公司之交易

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 二零二一年	2020 二零二零年
		HK$'000 千港元	HK$'000 千港元
		(unaudited) （未經審核）	(unaudited) （未經審核）
Interest income	利息收入	**751**	426
Rental and utilities income	租金及公共服務收入	**2,815**	300
Research and development service income	研究及開發服務收入	**21,671**	–
Purchase of consumables	採購消耗品	**1,045**	–

7. RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Compensation of key management personnel

The remuneration of directors and other members of key management during the period were as follows:

7. 關聯方交易(續)

(b) 主要管理人員之薪酬

於期內，董事及其他主要管理人員之薪酬如下：

		For the three months ended 31 March 截至三月三十一日止三個月	
		2021 **二零二一年** **HK$'000** **千港元** **(unaudited)** **(未經審核)**	2020 二零二零年 HK$'000 千港元 (unaudited) (未經審核)
Short-term employee benefits	短期僱員福利	**3,287**	5,943
Share-based payments	以股份支付之款項	**1,892**	790
Retirement and other post-employment benefits	退休及其他離職後福利	**3,005**	5,039
– Defined contribution plan	－定額供款計劃	**5**	9
– Retirement benefits	－退休福利	**3,000**	5,030
		8,184	11,772

(c) Donation to Lee's Pharmaceutical – Kanya Lee Scholarship Limited ("Kanya Lee Scholarship")

During the three months ended 31 March 2021, total HK$500,000 (three months ended 31 March 2020: HK$1,175,000) was donated to Kanya Lee Scholarship. Dr. Li Xiaoyi, director of the Company, is also a member of key management of Kanya Lee Scholarship and Kanya Lee Scholarship is considered as a related party of the Group.

(c) 向李氏大藥廠－李杜靜芳獎學金有限公司(「李杜靜芳獎學金」)作出捐獻

於截至二零二一年三月三十一日止三個月內，向李杜靜芳獎學金捐獻合共500,000港元(截至二零二零年三月三十一日止三個月：1,175,000港元)。本公司董事李小羿博士亦為李杜靜芳獎學金之主要管理層成員之一，而李杜靜芳獎學金被視為本集團之關聯方。

7. RELATED PARTY TRANSACTIONS (CONTINUED)

(d) Issue of subsidiary's shares to Perfect Concept Holdings Limited ("PCH")

During the three months ended 31 March 2020, China Oncology Focus Limited, on a pro rata basis, issued 18,620 shares to PCH. Ms. Leelalertsuphakun Wanee, Ms. Lee Siu Fong and Dr. Li Xiaoyi were both the directors of the Company and the substantial shareholders of PCH and PCH was considered as a related party to the Group. Total consideration received for the issue of shares thereto was US$4,003,300 (equivalent to approximately HK$31,226,000). No such event has occurred during the three months ended 31 March 2021.

(e) Interest expenses for shareholder loans from PCH

During the three months ended 31 March 2020, included in finance costs there was interest expenses for loans from PCH amounting to HK$147,000. Loans from PCH were fully settled in year 2020 and no interest expenses was incurred during the three months ended 31 March 2021.

7. 關聯方交易(續)

(d) 發行附屬公司股份予美創集團有限公司(「美創集團」)

於截至二零二零年三月三十一日止三個月內，中國腫瘤醫療有限公司按比例發行18,620股股份予美創集團。李燁妮女士、李小芳女士及李小羿博士均為本公司董事及美創集團之主要股東，故美創集團被視為本集團之關聯方。就發行股份收取之總代價為4,003,300美元(相當於約31,226,000港元)。於截至二零二一年三月三十一日止三個月內並無發生有關事項。

(e) 來自美創集團之股東貸款之利息開支

於截至二零二零年三月三十一日止三個月內，財務成本包括來自美創集團之貸款之利息開支147,000港元。來自美創集團之貸款已於二零二零年度全數結清，於截至二零二一年三月三十一日止三個月內並無產生任何利息開支。

8. CAPITAL COMMITMENTS

8. 資本承擔

		31 March 2021 二零二一年 三月三十一日 HK$'000 千港元 (unaudited) （未經審核）	31 December 2020 二零二零年 十二月三十一日 HK$'000 千港元 (audited) （經審核）
Capital commitments contracted for in respect of:	有關下列各項之已訂約資本承擔：		
Investment in financial assets at fair value through other comprehensive income	於按公平值透過其他全面收益列賬之財務資產之投資	10,750	10,750
Intangible assets – license fee and development cost	無形資產－專利費及開發成本	91,075	88,458
Property, plant and equipment	物業、廠房及設備	88,023	91,212
		189,848	190,420

9. EVENTS AFTER THE REPORTING PERIOD

Subsequent to the reporting period, the Group's then associate Zhaoke Ophthalmology Limited ("**ZKO**") was listed on the Main Board of The Stock Exchange of Hong Kong Limited on 29 April 2021. Following the listing by ZKO, the Company, through a wholly-owned subsidiary, indirectly hold approximately 25.8% of the total issued share of ZKO. ZKO ceased to be an associate of the Group since the Group will not exercise significant influence over the operation of ZKO. The Group's investment in ZKO is hence accounted for as financial assets at fair value through other comprehensive income for financial reporting purposes. Immediately after the listing of ZKO, the Group recorded a gain of approximately HK$2.32 billion in the Company's consolidated statement of profit or loss on this derecognition of investment in ZKO as an associate of the Group.

9. 報告期後事項

於報告期後，本集團當時之聯營公司兆科眼科有限公司(「**兆科眼科**」)於二零二一年四月二十九日在香港聯合交易所有限公司主板上市。隨着兆科眼科上市，本公司經由一間全資附屬公司間接持有兆科眼科全部已發行股份約25.8%。兆科眼科不再為本集團之聯營公司，因本集團對兆科眼科之營運再無重大影響力。因此，就財務申報目的而言，本集團於兆科眼科之投資乃入賬列作按公平值透過其他全面收益列賬之財務資產。緊隨兆科眼科上市後，本集團就終止確認於兆科眼科(作為本集團聯營公司)之投資於本公司之綜合損益表錄得收益約23.2億港元。

DIVIDEND

The Board does not recommend payment of dividend for the three months ended 31 March 2021 (three months ended 31 March 2020: Nil).

股息

董事會不建議派付截至二零二一年三月三十一日止三個月之股息(截至二零二零年三月三十一日止三個月：無)。

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the three months ended 31 March 2021.

購買、出售或贖回上市證券

於截至二零二一年三月三十一日止三個月內，本公司或其任何附屬公司並無購買、出售或贖回本公司任何上市證券。

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

承董事會命
李氏大藥廠控股有限公司
主席
李小芳

Hong Kong, 27 May 2021

香港，二零二一年五月二十七日

As at the date of this report, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi and Mr. Simon Miles Ball are non-executive Directors; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl, are independent non-executive Directors.

於本報告日期，執行董事為李小芳女士(主席)及李燁妮女士；非執行董事為李小羿博士及Simon Miles Ball先生；獨立非執行董事為陳友正博士、林日昌先生及詹華強博士。

LEE'S PHARM.

李 氏 大 藥 廠